Trials / Completed
CompletedNCT00204529
Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB
Randomized, Multicenter, Open Label Study to Compare the Efficacy and Tolerability of Pegylated Interferon-alpha-2 (PEG-IFN) to 'Low-dose' Interferon-alpha-2a in Patients With Malignant Melanoma in Stages IIA (T3a) - IIIB (AJCC 2002)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 901 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of adjuvant treatment with pegylated interferon-α-2a (PEG-IFN) vs. 'low dose' interferon-α-2a in patients with malignant melanoma in stage IIA (T3a) - IIIB. A total of 880 will be randomized up to three months after first surgical management of their melanoma to either: PEG-IFN-α-2a or low-dose interferon-α-2a.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegylated interferon-alpha-2a | |
| DRUG | interferon-alpha-2a |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2013-05-01
- Completion
- 2016-12-01
- First posted
- 2005-09-20
- Last updated
- 2017-05-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00204529. Inclusion in this directory is not an endorsement.